Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use in Individuals at Risk for HCV Infection or Presenting With Signs and Symptoms of HCV Infection by Untrained Operators in the United States

NCT07904416 is registered in ClinicalTrials.gov with bioLytical Laboratories as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use in Individuals at Risk for HCV Infection or Presenting With Signs and Symptoms of HCV Infection by Untrained Operators in the United States
Lead sponsor
bioLytical Laboratories
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
July 1, 2027
Enrollment
388 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hcv infection

Arms

As registered; 2 arms.

  • At Risk for HCV infection ExperimentalINSTI HCV Antibody Test

    Participants at risk of HCV infection must have at least one of the following:

    * Participants with past or present IV Drug Use
    * Participants on long-term hemodialysis
    * Participants with HIV positive status
    * Having received a blood transfusion or organ transplant prior to 1992
    * Healthcare workers with known exposure to needle sticks of HCV-positive blood
    * Participants with Chronic Hepatitis B Virus (HBV), Liver Cirrhosis, cancer, and/or hepatocellular carcinoma
    * Recipients of blood or organs from a donor who tested HCV positive
    * Being born to an HCV positive mother
    * History of incarceration
    * Participants who have unprotected vaginal, anal, or oral intercourse or multiple sexual partners
    * Men who have sex with men (MSM) and who are sexually active with an infected person
    * Participants sharing personal care items, such as toothbrushes, scissors, and razors
    * Participants receiving tattoos and body piercings with unsterile equipment

  • Signs or Symptoms of HCV Infection ExperimentalINSTI HCV Antibody Test

    Participants with signs or symptoms correlated with hepatitis, such as:

    • Jaundice (yellow discoloration of the skin and eyes)

    Or, a combination of two or more generalized symptoms, such as:

    * Ascites (accumulation of fluid and swelling of the abdominal cavity)
    * Star-shaped vein pattern developing on the swollen belly
    * Dark-colored urine
    * Light-colored bowel movement
    * Easy bruising and bleeding
    * Abdominal and joint pain
    * Nausea/vomiting
    * Loss of appetite
    * Diarrhea
    * Fatigue
    * Itching
    * Fever

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Performance Evaluation 6 months

    To establish the positive and negative percent agreement of INSTI HCV performed with fingerstick whole blood compared to a comparator test in the hands of untrained operators at CLIA Waived settings. HCV RNA PCR will be used to establish HCV infection status.

Lead sponsor's other trials

bioLytical Laboratories, most recent start first.

Similar trials

Same condition (Hepatitis C) and phase, most recent start first.